LAVA Therapeutics (LVTX) has released an update.
LAVA Therapeutics advances in cancer treatment with its innovative Gammabody® platform, focusing on the selective activation of Gamma-Delta T cells for a larger therapeutic window and reduced toxicities. Their lead program LAVA-1207, targeting metastatic castration-resistant prostate cancer, is progressing in clinical trials with a new combination arm expected to launch soon. The company boasts a strong cash position, expected to last into 2026, and several strategic partnerships, including collaborations with Pfizer and Johnson & Johnson.
For further insights into LVTX stock, check out TipRanks’ Stock Analysis page.
